★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Eli Lilly and Company (LLY) Moat Analysis
Eli Lilly and Company
LLY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Eli Lilly is a pharmaceutical company increasingly concentrated in cardiometabolic medicines: Mounjaro and Zepbound generated 65% of Q1 2026 revenue, and cardiometabolic products were about 80%. Its clearest moat is time-limited patent and regulatory exclusivity around differentiated medicines, reinforced in incretins by exceptional internal manufacturing investment and launch scale. Foundayo gained U.S. obesity approval in April 2026, broadening Lilly's franchise to an oral GLP-1. General R&D capability, regulatory compliance and planned modality capacity are not counted as stand-alone moats because large peers possess similar capabilities. Key risks are patent expiry, clinical displacement, payer and government price pressure, product concentration, safety findings and manufacturing execution.
Primary segment
Cardiometabolic Health
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
5 segments · 9 tags
Updated 2026-07-12
Segments
Cardiometabolic Health
Cardiometabolic pharmaceuticals (diabetes, obesity, and related metabolic diseases)
Revenue
79.6%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Oncology
Oncology branded therapeutics (solid tumors and hematologic malignancies)
Revenue
11.5%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Immunology
Immunology and inflammatory disease therapeutics (biologics and small molecules)
Revenue
6.1%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Neuroscience
Neuroscience therapeutics (migraine, neurodegenerative disease, and other CNS conditions)
Revenue
1.9%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Other
Other pharmaceutical products and collaboration/royalty revenue
Revenue
0.9%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
Cardiometabolic Health
Cardiometabolic pharmaceuticals (diabetes, obesity, and related metabolic diseases)
Revenue share uses Q1 2026 Form 10-Q revenue disaggregation: Cardiometabolic Health revenue $15.760B / total revenue $19.799B.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Cardiometabolic blockbusters (notably tirzepatide) are protected by patents and regulatory/data protections that delay generic entry.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges or earlier-than-expected loss of exclusivity
- Rapid competitor innovation (next-gen incretins, oral GLP-1s) reducing differentiation pre-LOE
- Regulatory changes affecting data/package exclusivity
Leading indicators
- Patent litigation outcomes and settlement dates
- Regulatory exclusivity changes (e.g., data-package rules)
- Competitor trial readouts in obesity/diabetes
Counterarguments
- IP protection is time-limited; post-LOE price erosion can be rapid
- Competitors can innovate around claims (new molecules/delivery) before LOE
Capacity Moat
Supply
Capacity Moat
Strength
Durability
Confidence
Evidence
Lilly is making unusually large, multi-year investments in internal incretin API, injectable and oral-drug production, providing some supply and launch-scale advantage while new capacity is commissioned.
Capacity Moat moat: definition, examples, and stocks
Erosion risks
- Execution risk: delays in new capacity, quality issues, or regulatory actions at plants
- Third-party/CMO constraints for devices/fill-finish/inputs
- Demand normalization reducing scarcity premium
Leading indicators
- Backorder status / supply constraints for key SKUs
- Capex run-rate and plant commissioning milestones
- FDA inspection outcomes and warning letters (if any)
Counterarguments
- Competitors can also invest; capacity advantages may narrow over time
- Capacity does not guarantee pricing power if payer coverage is constrained
Oncology
Oncology branded therapeutics (solid tumors and hematologic malignancies)
Revenue share uses Q1 2026 Form 10-Q revenue disaggregation: Oncology revenue $2.268B / total revenue $19.799B.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Key oncology assets (e.g., Verzenio, Retevmo, Jaypirca) are protected by patents and regulatory protections that support returns on innovation during exclusivity windows.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity and biosimilar/generic entry
- Patent litigation or design-around strategies
- Price pressure from payers and government programs
Leading indicators
- IP litigation status and patent expiry timeline updates
- Biosimilar pipeline announcements in key molecules/classes
- Net price and gross-to-net trends
Counterarguments
- Exclusivity is temporary; oncology LOE can cause sharp revenue declines
- Competitors can displace branded drugs via superior efficacy or tolerability before LOE
Immunology
Immunology and inflammatory disease therapeutics (biologics and small molecules)
Revenue share uses Q1 2026 Form 10-Q revenue disaggregation: Immunology revenue $1.203B / total revenue $19.799B.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Biologics and differentiated immunology assets (e.g., Taltz, Omvoh, Ebglyss) are protected by patents and regulatory protections that delay biosimilar entry.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Biosimilar competition after exclusivity loss
- Formulary-driven switching and aggressive rebating
- Safety/label changes impacting prescriber confidence
Leading indicators
- Biosimilar filings/launch timing for key molecules
- Formulary status changes and rebate levels (gross-to-net)
- Adverse-event trends and label updates
Counterarguments
- Immunology categories are competitive; payers often force price competition
- Biosimilar entry can erode volume and price quickly after LOE
Neuroscience
Neuroscience therapeutics (migraine, neurodegenerative disease, and other CNS conditions)
Revenue share uses Q1 2026 Form 10-Q revenue disaggregation: Neuroscience revenue $382M / total revenue $19.799B.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Key neuroscience products are protected by patents and/or biologics data protections that support exclusivity-driven economics during the protection window.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Post-LOE generic/biosimilar erosion
- Safety signals (especially in neurodegenerative indications)
- Competitive displacement by superior efficacy/tolerability
Leading indicators
- Patent timeline updates and litigation status
- Real-world safety data and label changes
- Competitive approvals and head-to-head evidence
Counterarguments
- CNS markets can shift quickly with new clinical data; patents do not guarantee durable share
- Payers can restrict high-cost therapies (step edits, prior auth)
Other
Other pharmaceutical products and collaboration/royalty revenue
Revenue share uses Q1 2026 Form 10-Q revenue disaggregation: Other revenue $187M / total revenue $19.799B.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
Patent/data protection table lists estimated expiry dates for Mounjaro/Zepbound (tirzepatide) across U.S., Europe, and Japan, supporting an IP-based moat during the exclusivity window.
Lilly says significant manufacturing expansions are underway and additional capacity is expected to come online over several years.
The additional commitment brings Lilly's Indiana expansion commitments since 2020 above $21 billion and includes planned Foundayo and retatrutide production.
Risks & Indicators
Erosion risks
- Patent challenges or earlier-than-expected loss of exclusivity
- Rapid competitor innovation (next-gen incretins, oral GLP-1s) reducing differentiation pre-LOE
- Regulatory changes affecting data/package exclusivity
- Execution risk: delays in new capacity, quality issues, or regulatory actions at plants
- Third-party/CMO constraints for devices/fill-finish/inputs
- Demand normalization reducing scarcity premium
Leading indicators
- Patent litigation outcomes and settlement dates
- Regulatory exclusivity changes (e.g., data-package rules)
- Competitor trial readouts in obesity/diabetes
- Backorder status / supply constraints for key SKUs
- Capex run-rate and plant commissioning milestones
- FDA inspection outcomes and warning letters (if any)
Research LLY elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.